Skip to main content
. 2016 Dec 19;127(2):457–471. doi: 10.1172/JCI85145

Figure 6. VEGFR-2 inhibitors suppress tumor growth, increase the number of functional vessels, and improve the survival of tumor-bearing CLEC14A-KO mice.

Figure 6

(A) Growth curves of B16F10-derived tumors treated with vehicle (DMSO), sunitinib, or DMH4. n = 6 per group. (B) Size of captured B16F10 tumors under the different treatment conditions. (C) Survival curves of B16F10-injected WT and CLEC14A-KO mice treated with vehicle, sunitinib, or DMH4. n = 6 per group. (D) Images of B16F10 tumor masses before capture from WT and CLEC14A-KO mice treated with DMSO, sunitinib, or DMH4. (E) Immunostaining for CD31 and lectin as well as FITC-dextran and DAPI staining showing reduced leakage and increased numbers of functional vessels in mice treated with sunitinib or DMH4 compared with those treated with vehicle. Scale bars: 100 μm. (F and G) Quantification of functional vessels and FITC-dextran leakage in tumors from WT and CLEC14A-KO mice treated with DMSO, sunitinib, or DMH4. n = 6 per group. *P < 0.05, **P < 0.005, and ***P < 0.0001, by paired, 2-tailed Student’s t test. Error bars represent the mean ± SD.